Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...